Investigation of demographic features, performance, comorbidity status and mortality causes among multiple myeloma patients: real-life data
CONCLUSION: Among the scoring systems utilised, R-MCI was more convenient to apply due to its ease of use and practicality. Our study supports the heterogeneous course of myeloma and highlights geographic differences including comorbidities, causes of death and overall survival.PMID:34319819 | DOI:10.1080/17474086.2021.1962279 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 28, 2021 Category: Hematology Authors: Tu ğba Şahin Atakan Turgutkaya G ürhan Kadıköylü Ali Zahit Bolaman İrfan Yavaşoğlu Source Type: research

Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia
Expert Rev Hematol. 2021 Jul 27. doi: 10.1080/17474086.2021.1960817. Online ahead of print.ABSTRACTINTRODUCTION: The long-term survival of relapsed/refractory (R/R) adult T-cell acute lymphoblastic leukemia (T-ALL) is quite poor, and early T-cell precursor (ETP) ALL has recently been described as a high-risk T-ALL subgroup. However, the optimal therapeutic approach to R/R adult T-ALL remains poorly established.AREAS COVERED: At present, cytoreductive therapy followed by allogeneic stem cell transplantation (allo-SCT) is considered to be the most clinically relevant and curative modality for R/R T-ALL. Above all, achieving ...
Source: Expert Review of Hematology - July 27, 2021 Category: Hematology Authors: Dong Won Baek Jung Min Lee Juhyung Kim Hee Jeong Cho Joon Ho Moon Sang Kyun Sohn Source Type: research

Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients
Expert Rev Hematol. 2021 Jul 23. doi: 10.1080/17474086.2021.1960816. Online ahead of print.ABSTRACTINTRODUCTION: : Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe complication of transplant. TA-TMA is a multifactorial disease where generalized endothelial dysfunction leads to microangiopathic hemolytic anemia, intravascular platelet activation, and formation of microthrombi leading to end-organ injury. It is essential to identify patients at risk for this complication and to implement early interventions to improve TA-TMA associated transplant outcomes.AREAS COVERED: : Rec...
Source: Expert Review of Hematology - July 24, 2021 Category: Hematology Authors: Sonata Jodele Anthony Sabulski Source Type: research

Subclinical Atherosclerotic Predictive Value of Inflammatory Markers in Thalassemia Intermedia Patients
CONCLUSION: β- TI patients had higher CIMT despite the protective lipid profile. Hs-CRP was an independent predictor of CIMT.PMID:34296962 | DOI:10.1080/17474086.2021.1959316 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 23, 2021 Category: Hematology Authors: Osama Ahmad Ibrahim Ahmad B Ahmad Dalia Ahmad Nigm Asmaa Nady Hussien Walaa H Mohammad Ibrahim Source Type: research

Avapritinib: an emerging new therapy for systemic mastocytosis
Expert Rev Hematol. 2021 Jul 21. doi: 10.1080/17474086.2021.1959315. Online ahead of print.ABSTRACTINTRODUCTION: Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating KIT mutations, usually D816V. SM can be indolent (ISM), smoldering (SSM) and advanced (AdvSM), the latter characterized by organ damage resulting from infiltrating neoplastic mast cells. The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM, comprising aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia, however, carries a poor ...
Source: Expert Review of Hematology - July 22, 2021 Category: Hematology Authors: Prithviraj Bose Srdan Verstovsek Source Type: research

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Expert Rev Hematol. 2021 Jul 19. doi: 10.1080/17474086.2021.1956898. Online ahead of print.ABSTRACTINTRODUCTION: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly.AREAS COVERED: Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: In és Gómez-Seguí Cristina Pascual Izquierdo Javier de la Rubia Comos Source Type: research

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
CONCLUSION: Brentuximab vedotin had a positive benefit-risk profile for Chinese patients with R/R cHL or sALCL confirming it as a potential treatment option.CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT02939014.PMID:34275403 | DOI:10.1080/17474086.2021.1942831 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Yuqin Song Ye Guo Huiqiang Huang Wei Li Xiaoyan Ke Jifeng Feng Wei Xu Harry Miao Judith Kinley Gregory Song Yi Dai Hui Wang Jun Zhu Source Type: research

Overcoming the challenges of treating haemophilia in resource-limited nations: a focus on medication access and adherence
Expert Rev Hematol. 2021 Jul 18. doi: 10.1080/17474086.2021.1957826. Online ahead of print.ABSTRACTBACKGROUND: Haemophilia is a high cost low volume disease. Resource limited nations (RLN) usually spend very little on health budget and most of it is spent in dealing with common ailments. Clotting products constitute more than 90 percent of the total cost of haemophilia care. The manner in which these products can be made accessible for persons with haemophilia (PWH) and how its continuous supply and distribution can be maintained and improved is described in this review.AREAS COVERED: Number of PWH in the Resource Limited ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Kanjaksha Ghosh Kinjalka Ghosh Source Type: research

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Expert Rev Hematol. 2021 Jul 19. doi: 10.1080/17474086.2021.1956898. Online ahead of print.ABSTRACTINTRODUCTION: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly.AREAS COVERED: Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: In és Gómez-Seguí Cristina Pascual Izquierdo Javier de la Rubia Comos Source Type: research

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
CONCLUSION: Brentuximab vedotin had a positive benefit-risk profile for Chinese patients with R/R cHL or sALCL confirming it as a potential treatment option.CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT02939014.PMID:34275403 | DOI:10.1080/17474086.2021.1942831 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Yuqin Song Ye Guo Huiqiang Huang Wei Li Xiaoyan Ke Jifeng Feng Wei Xu Harry Miao Judith Kinley Gregory Song Yi Dai Hui Wang Jun Zhu Source Type: research

Overcoming the challenges of treating haemophilia in resource-limited nations: a focus on medication access and adherence
Expert Rev Hematol. 2021 Jul 18. doi: 10.1080/17474086.2021.1957826. Online ahead of print.ABSTRACTBACKGROUND: Haemophilia is a high cost low volume disease. Resource limited nations (RLN) usually spend very little on health budget and most of it is spent in dealing with common ailments. Clotting products constitute more than 90 percent of the total cost of haemophilia care. The manner in which these products can be made accessible for persons with haemophilia (PWH) and how its continuous supply and distribution can be maintained and improved is described in this review.AREAS COVERED: Number of PWH in the Resource Limited ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Kanjaksha Ghosh Kinjalka Ghosh Source Type: research

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Expert Rev Hematol. 2021 Jul 19. doi: 10.1080/17474086.2021.1956898. Online ahead of print.ABSTRACTINTRODUCTION: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly.AREAS COVERED: Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: In és Gómez-Seguí Cristina Pascual Izquierdo Javier de la Rubia Comos Source Type: research

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
CONCLUSION: Brentuximab vedotin had a positive benefit-risk profile for Chinese patients with R/R cHL or sALCL confirming it as a potential treatment option.CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT02939014.PMID:34275403 | DOI:10.1080/17474086.2021.1942831 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Yuqin Song Ye Guo Huiqiang Huang Wei Li Xiaoyan Ke Jifeng Feng Wei Xu Harry Miao Judith Kinley Gregory Song Yi Dai Hui Wang Jun Zhu Source Type: research

Overcoming the challenges of treating haemophilia in resource-limited nations: a focus on medication access and adherence
Expert Rev Hematol. 2021 Jul 18. doi: 10.1080/17474086.2021.1957826. Online ahead of print.ABSTRACTBACKGROUND: Haemophilia is a high cost low volume disease. Resource limited nations (RLN) usually spend very little on health budget and most of it is spent in dealing with common ailments. Clotting products constitute more than 90 percent of the total cost of haemophilia care. The manner in which these products can be made accessible for persons with haemophilia (PWH) and how its continuous supply and distribution can be maintained and improved is described in this review.AREAS COVERED: Number of PWH in the Resource Limited ...
Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Kanjaksha Ghosh Kinjalka Ghosh Source Type: research

The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
This article reviews the literature on CD30-related biology, prevalence, and therapy in patients with PTCL or CTCL. We searched the PubMed database from 1 January 2010 to 28 April 2020, using terms 'CD30' ('peripheral T-cell lymphomas' or 'cutaneous T-cell lymphoma') and 'immunohistochemistry' or 'flow cytometry' or 'pathology', and synonyms including terms for T-cell lymphoma subtypes.EXPERT OPINION: CD30 is expressed at relatively high rates of prevalence across a broad range of PTCLs and CTCLs. CD30 expression may be critical to the development of a subset of PTCLs and also a biomarker for treatment choice in some subty...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Kennosuke Karube Yoshihide Kakimoto Yukio Tonozuka Koichi Ohshima Source Type: research

Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies
Expert Rev Hematol. 2021 Jul 15. doi: 10.1080/17474086.2021.1955345. Online ahead of print.ABSTRACTINTRODUCTION: Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy characterized by the EBV-driven proliferation of mature natural killer cells. It mostly frequently affects younger adults and has a fulminant course with a median overall survival of 2 months. Challenges in managing this disease include an aggressive clinical course, hematologic complications, limited clinical evidence, and a lack of consensus on therapeutic strategies.AREAS COVERED: Here, authors reviewed the key aspects of the epid...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Yumeng Zhang Dasom Lee Quinto Gesiotto Lubomir Sokol Source Type: research

The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
This article reviews the literature on CD30-related biology, prevalence, and therapy in patients with PTCL or CTCL. We searched the PubMed database from 1 January 2010 to 28 April 2020, using terms 'CD30' ('peripheral T-cell lymphomas' or 'cutaneous T-cell lymphoma') and 'immunohistochemistry' or 'flow cytometry' or 'pathology', and synonyms including terms for T-cell lymphoma subtypes.EXPERT OPINION: CD30 is expressed at relatively high rates of prevalence across a broad range of PTCLs and CTCLs. CD30 expression may be critical to the development of a subset of PTCLs and also a biomarker for treatment choice in some subty...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Kennosuke Karube Yoshihide Kakimoto Yukio Tonozuka Koichi Ohshima Source Type: research

Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies
Expert Rev Hematol. 2021 Jul 15. doi: 10.1080/17474086.2021.1955345. Online ahead of print.ABSTRACTINTRODUCTION: Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy characterized by the EBV-driven proliferation of mature natural killer cells. It mostly frequently affects younger adults and has a fulminant course with a median overall survival of 2 months. Challenges in managing this disease include an aggressive clinical course, hematologic complications, limited clinical evidence, and a lack of consensus on therapeutic strategies.AREAS COVERED: Here, authors reviewed the key aspects of the epid...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Yumeng Zhang Dasom Lee Quinto Gesiotto Lubomir Sokol Source Type: research

The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
This article reviews the literature on CD30-related biology, prevalence, and therapy in patients with PTCL or CTCL. We searched the PubMed database from 1 January 2010 to 28 April 2020, using terms 'CD30' ('peripheral T-cell lymphomas' or 'cutaneous T-cell lymphoma') and 'immunohistochemistry' or 'flow cytometry' or 'pathology', and synonyms including terms for T-cell lymphoma subtypes.EXPERT OPINION: CD30 is expressed at relatively high rates of prevalence across a broad range of PTCLs and CTCLs. CD30 expression may be critical to the development of a subset of PTCLs and also a biomarker for treatment choice in some subty...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Kennosuke Karube Yoshihide Kakimoto Yukio Tonozuka Koichi Ohshima Source Type: research

Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies
Expert Rev Hematol. 2021 Jul 15. doi: 10.1080/17474086.2021.1955345. Online ahead of print.ABSTRACTINTRODUCTION: Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy characterized by the EBV-driven proliferation of mature natural killer cells. It mostly frequently affects younger adults and has a fulminant course with a median overall survival of 2 months. Challenges in managing this disease include an aggressive clinical course, hematologic complications, limited clinical evidence, and a lack of consensus on therapeutic strategies.AREAS COVERED: Here, authors reviewed the key aspects of the epid...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Yumeng Zhang Dasom Lee Quinto Gesiotto Lubomir Sokol Source Type: research

The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
This article reviews the literature on CD30-related biology, prevalence, and therapy in patients with PTCL or CTCL. We searched the PubMed database from 1 January 2010 to 28 April 2020, using terms 'CD30' ('peripheral T-cell lymphomas' or 'cutaneous T-cell lymphoma') and 'immunohistochemistry' or 'flow cytometry' or 'pathology', and synonyms including terms for T-cell lymphoma subtypes.EXPERT OPINION: CD30 is expressed at relatively high rates of prevalence across a broad range of PTCLs and CTCLs. CD30 expression may be critical to the development of a subset of PTCLs and also a biomarker for treatment choice in some subty...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Kennosuke Karube Yoshihide Kakimoto Yukio Tonozuka Koichi Ohshima Source Type: research

Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies
Expert Rev Hematol. 2021 Jul 15. doi: 10.1080/17474086.2021.1955345. Online ahead of print.ABSTRACTINTRODUCTION: Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy characterized by the EBV-driven proliferation of mature natural killer cells. It mostly frequently affects younger adults and has a fulminant course with a median overall survival of 2 months. Challenges in managing this disease include an aggressive clinical course, hematologic complications, limited clinical evidence, and a lack of consensus on therapeutic strategies.AREAS COVERED: Here, authors reviewed the key aspects of the epid...
Source: Expert Review of Hematology - July 15, 2021 Category: Hematology Authors: Yumeng Zhang Dasom Lee Quinto Gesiotto Lubomir Sokol Source Type: research

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma
Expert Rev Hematol. 2021 Jul 12. doi: 10.1080/17474086.2021.1950529. Online ahead of print.ABSTRACTINTRODUCTION: While there has been an improvement in the treatment of mantle cell lymphoma (MCL) in both median progression-free survival (PFS;>7-8 years) and overall survival (OS;>10-12 years), patients with high-risk features such as high risk MIPI (mantle cell international prognostic index), high Ki-67 (≥30%), or blastoid variants still carry poor outcome with a median OS of 3 years. Furthermore, patients with high-risk molecular features, such as TP53 mutations, show dismal outcome, with a median OS of 1.8 years...
Source: Expert Review of Hematology - July 13, 2021 Category: Hematology Authors: Andre Goy Source Type: research

Managing complications secondary to Waldenstr öm's macroglobulinemia
Expert Rev Hematol. 2021 Jul 2:1-12. doi: 10.1080/17474086.2021.1947236. Online ahead of print.ABSTRACTIntroduction: Waldenström's macroglobulinemia (WM) is a rare lymphoma characterized by the accumulation of IgM-secreting lymphoplasmacytic cells in the bone marrow and other organs. Clinical sequelae relate to direct tissue infiltration by malignant cells but also to the physicochemical and immunological properties of the monoclonal IgM, resulting in a variety of disease-related complications.Areas covered: This narrative review, following a thorough Pubmed search of pertinent published literature, discusses complica...
Source: Expert Review of Hematology - June 25, 2021 Category: Hematology Authors: Ilias Pessach Meletios A Dimopoulos Efstathios Kastritis Source Type: research

Managing complications secondary to Waldenstr öm's macroglobulinemia
Expert Rev Hematol. 2021 Jun 25. doi: 10.1080/17474086.2021.1947236. Online ahead of print.ABSTRACTIntroduction: Waldenström's macroglobulinemia (WM) is a rare lymphoma characterized by the accumulation of IgM-secreting lymphoplasmacytic cells in the bone marrow and other organs. Clinical sequelae relate to direct tissue infiltration by malignant cells but also to the physicochemical and immunological properties of the monoclonal IgM, resulting in a variety of disease-related complications.Areas covered: This narrative review, following a thorough Pubmed search of pertinent published literature, discusses complication...
Source: Expert Review of Hematology - June 25, 2021 Category: Hematology Authors: Ilias Pessach Meletios A Dimopoulos Efstathios Kastritis Source Type: research

Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts
Expert Rev Hematol. 2021 Jun 23. doi: 10.1080/17474086.2021.1947791. Online ahead of print.ABSTRACTINTRODUCTION: Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell diseases characterized by cell dysplasia, ineffective hematopoiesis and risk of transformation to acute myeloid leukemia (AML). The median age of 75 years at diagnosis is associated with the presence of comorbidities, which preclude intensive therapies like allogeneic hematopoietic stem cell transplantation in most MDS patients. Risk stratification using the (Revised) International Prognostic Scoring System (IPSS/IPSS-R) is nece...
Source: Expert Review of Hematology - June 23, 2021 Category: Hematology Authors: Felicitas Schulz Kathrin Nachtkamp Annika Kasprzak Norbert Gattermann Rainer Haas Ulrich Germing Source Type: research

Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions
Expert Rev Hematol. 2021 Jun 21. doi: 10.1080/17474086.2021.1944096. Online ahead of print.ABSTRACTINTRODUCTION: Myelofibrosis (MF) is a complex and aggressive hematologic malignancy resulting from JAK/STAT-driven myeloproliferation and abnormal fibrogenesis. The clinical manifestations are heterogeneous and include splenomegaly, constitutional symptoms, cytopenias, impaired quality of life, and shortened survival. JAK inhibitors improve symptoms and splenomegaly to a variable degree in a proportion of patients, but the effects for many patients are insufficient or short-lived.AREAS COVERED: This review examines the conste...
Source: Expert Review of Hematology - June 21, 2021 Category: Hematology Authors: James Yoon Kristen Pettit Source Type: research

Construction of prognostic marker for diffuse large b-cell lymphoma based on tumor microenvironment
In this study, we aim to identify a potential biomarker by analyzing gene expression data, and to predict patient's survival rate by constructing a risk model.METHODS: Firstly, mRNA chip data (GSE87371) and clinical data of DLBCL patients were obtained from Gene Expression Omnibus (GEO). Samples were scored with estimate package. The obtained stromal score (P
Source: Expert Review of Hematology - June 18, 2021 Category: Hematology Authors: Ganggang Wang Chen Qiu Chan Zhang Shuling Hou Qiaohua Zhang Source Type: research

An expert spotlight on inferior vena cava filters
Expert Rev Hematol. 2021 Jun 18. doi: 10.1080/17474086.2021.1943350. Online ahead of print.ABSTRACTIntroduction: Inferior vena cava (IVC) filters are mechanical filtration devices designed as an alternative to surgical ligation/plication of the IVC. Their use has been controversial, especially with the introduction of retrievable filters and expanded/prophylactic indications.Areas covered: Authors discuss the types of available IVC filters, indications for placement, evidence on their effectiveness in general and specific patient populations, procedural considerations, off-label use, complications and filter retrieval. Thi...
Source: Expert Review of Hematology - June 18, 2021 Category: Hematology Authors: Anil Pillai Manoj Kathuria Maria Del Pilar Bayona Molano Patrick Sutphin Sanjeeva P Kalva Source Type: research

Construction of prognostic marker for diffuse large b-cell lymphoma based on tumor microenvironment
In this study, we aim to identify a potential biomarker by analyzing gene expression data, and to predict patient's survival rate by constructing a risk model.METHODS: Firstly, mRNA chip data (GSE87371) and clinical data of DLBCL patients were obtained from Gene Expression Omnibus (GEO). Samples were scored with estimate package. The obtained stromal score (P
Source: Expert Review of Hematology - June 18, 2021 Category: Hematology Authors: Ganggang Wang Chen Qiu Chan Zhang Shuling Hou Qiaohua Zhang Source Type: research